Cost-effectiveness analyses alongside randomised clinical trials

Clinical Trials

Volumn 3, Issue 6, 2006, Pages 538-542

  Gray, Alastair M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 34147222676     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774506073108     Document Type: Conference Paper

References (16)

1. Robbins L. An essay on the nature and significance of economic science (1932). Macmillan, 1932.
2. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-721.
3. Black WC. The CE plane: A graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212-214.
4. Van Hout B, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
5. Rawlins M. In pursuit of quality: The National Institute for Clinical Excellence [see comments]. Lancet 1999; 353: 1079-1082.
6. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. Br Med J 2004; 329: 224-227.
7. Williams A. What could be nicer than NICE? Office of Health Economics, 2004.
8. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.
9. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews. Stat Med 1987; 6: 245-254.
10. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty-when is there sufficient evidence? Value Health 2005; 8: 433-446.
11. Buxton MJ, Drummond MF, Van HB et al. Modelling in economic evaluation: an unavoidable fact of life [editorial]. Health Econ 1997; 6: 217-227.
12. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population. Br Med J 1996; 312: 1443-1448.
13. HPS Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
14. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20,536 individuals. Lancet 2005; 365: 1779-1785.
15. Clarke P, Gray A, Briggs A et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68). Diabetologia 2004; 47: 1747-1759.
16. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005; 48: 868-877.